Edwards Lifesciences Corporation
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000BRXP69
EW
Edwards Lifesciences Corporation
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Medical Devices
NAME
Edwards Lifesciences Corporation
ISIN
US28176E1082
TICKER
EW
MIC
XNYS
REUTERS
EW.N
BLOOMBERG
EW US
F&G:
62
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 06.05.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.
Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on...
Edwards Lifesciences
Do., 01.05.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.
Approval of the SAPIEN 3 platfo...
Edwards Lifesciences
Mi., 23.04.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025.
Recent Highlights
Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1
Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected
Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growt...
Edwards Lifesciences
Fr., 18.04.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves.
For more than 65 years, Edwards has been the leader in...
Edwards Lifesciences
Mi., 16.04.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be ava...
Edwards Lifesciences
Mo., 14.04.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the...
Edwards Lifesciences
Mo., 31.03.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease.
Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) ma...
Edwards Lifesciences
Di., 25.02.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.
Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at ...
Edwards Lifesciences
Di., 11.02.2025
Edwards Lifesciences
US28176E1082
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.
Highlights and Outlook
Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups
Q4 TAVR sales grew 6%; constant currency2 sales grew 5%
Q4 TMTT sales grew 88% to $105 million with i...
Edwards Lifesciences
Fr., 07.02.2025
Edwards Lifesciences
US28176E1082
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSE: EW).
On July 24, 2024, the Company announced its financial results for the second quarter of the Fiscal Y...
Edwards Lifesciences
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
